Ritesh Shrivastava

C92, a proton channel-blocking allosteric STING agonist generates robust antitumor activity

Monali Banerjee, Sandip Kumar Middya, Ritesh Shrivastava, Anindita Middya et autres

gb, fr (code pays fourni par la source)

Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

Ciara M. Kelly, Monali Banerjee, Reinhard von Roemeling, Alan L. Ho et autres

us (code pays fourni par la source)

Abstract CT295: Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors

Ciara M. Kelly, Reinhard von Roemeling, Monali Banerjee, Viswatej Avutu et autres

us, gb (code pays fourni par la source)

Abstract CT191: Intravenous infusion of the allosteric small molecule STING agonist CRD3874-SI in patients with relapsed or refractory acute myeloid leukemia: A phase I trial

Maria R. Baer, Vu H. Duong, Oyinkansola Arasanmi, Daisy Issac et autres

us, gb (code pays fourni par la source)

Synthesis and structure-activity evaluation of a series of novel tricyclic STING activators

Sourav Basu, Sandip Middya, Ritesh Shrivastava, David C. Pryde et autres

in (code pays fourni par la source)

COMPOUND 1 is a first-in-class small molecule cGAMP competitive oral STING antagonist that reduces lung inflammation and fibrosis in chronic bleomycin and silica mouse models

Monali Banerjee, Sandip Middya, Ritesh Shrivastava, Sourav Basu et autres

COMPOUND 2 is a first-in-class small molecule cGAMP competitive oral STING antagonist that reduces neuroinflammation in mouse models

Monali Banerjee, Ritesh Shrivastava, Sandip Middya, Sourav Basu et autres

Abstract 7481: The allosteric STING agonist CRD3874 is systemically tolerated demonstrates systemic tolerability

Monali Banerjee, Sandip Middya, Ritesh Shrivastava, Anindita Middya et autres

gb, fr (code pays fourni par la source)

Abstract 5322: Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity

Monali Banerjee, Ritesh Shrivastava, David C. Pryde, Sandip Middya et autres

gb (code pays fourni par la source)

782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity

Monali Banerjee, Sandip Middya, Ritesh Shrivastava, Anindita Middya et autres

fr (code pays fourni par la source)

Abstract 2122: CRD1600 is a potent HPK-I inhibitor with robust immune modulatory properties

Ritesh Shrivastava, David C. Pryde, Dharmendra Kumar Yadav, Abhisek Chatterjee et autres

gb (code pays fourni par la source)

Abstract 1996: Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors

Monali Banerjee, Sourav Basu, Sandip Middya, Ritesh Shrivastava et autres

gb (code pays fourni par la source)